Gene Editing, CRISPR & Synthetic Biology — Applications, Ethics & India's Policy

Gene editing — particularly CRISPR-Cas9 — has transformed biology in a decade from a laboratory tool into approved human therapies, making it among the most examined science-technology topics in UPSC GS3. It combines cutting-edge science with deep ethical, regulatory, and equity questions that the exam frequently probes.

1. DNA and Genetic Basics — A Brief Recap

• DNA (Deoxyribonucleic acid): The molecule carrying genetic instructions; composed of four nucleotide bases — Adenine (A), Thymine (T), Guanine (G), Cytosine (C)
• Gene: A specific sequence of DNA that codes for a protein
• Genome: The complete set of DNA in an organism; the human genome has approximately 3 billion base pairs and ~20,000–25,000 protein-coding genes
• Mutation: A change in the DNA sequence; can cause disease (e.g., sickle cell disease — a single base-pair substitution) or be neutral

Why gene editing matters: Many serious diseases — sickle cell anaemia, haemophilia, beta-thalassaemia, certain cancers, hereditary blindness — result from specific, identifiable genetic errors. The ability to precisely correct these errors is the promise of gene editing.

2. History of Gene Editing Technologies

3. CRISPR-Cas9 — Mechanism

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural immune system found in bacteria, which they use to recognise and cut the DNA of invading viruses.

Scientists harnessed and simplified this system for gene editing:

1. Guide RNA (gRNA): A short, synthetic RNA strand designed to match the exact DNA sequence to be edited; acts as a "GPS" to guide the Cas9 protein to the right location in the genome
2. Cas9 protein: Functions as "molecular scissors" — an endonuclease enzyme that cuts both strands of the DNA double helix at the target site
3. DNA repair: After the cut, the cell attempts to repair the break:
   • NHEJ (Non-Homologous End Joining): Imprecise; often introduces small insertions/deletions (indels) that disable the gene — useful for gene knock-out
   • HDR (Homology-Directed Repair): If a repair template is provided, allows precise substitution — useful for gene correction

Advanced variants:

• Base editing: Chemically converts one DNA base to another (e.g., A to G) without cutting the double strand — more precise, fewer off-target effects
• Prime editing: Described as a "search-and-replace" for the genome; uses a reverse transcriptase to write new genetic information; fewer off-target effects than original CRISPR-Cas9

4. Nobel Prize in Chemistry 2020

The 2020 Nobel Prize in Chemistry was jointly awarded to:

• Emmanuelle Charpentier (born 1968, France; Director, Max Planck Unit for the Science of Pathogens, Berlin)
• Jennifer A. Doudna (born 1964, USA; Professor, University of California, Berkeley)

"For the development of a method for genome editing."

They were the first two women to jointly win a Nobel Prize in the sciences. Their key contribution: in 2012, they published a landmark paper showing how CRISPR-Cas9 could be programmed with a guide RNA to cut any target DNA sequence — the invention that launched the modern gene-editing era.

5. Types of Gene Editing — Somatic vs Germline

This is the most important conceptual distinction for UPSC:

6. Key Milestones in Gene Therapy

Casgevy (Exagamglogene Autotemcel): The world's first approved CRISPR-based therapy.

• Approved by FDA: 8 December 2023
• Indication: Sickle cell disease (and later beta-thalassaemia) in patients aged 12 and older with recurrent vaso-occlusive crises
• How it works: Patient's blood stem cells are extracted, edited using CRISPR-Cas9 to reactivate fetal haemoglobin (HbF) production, then reinfused
• Results: In a clinical trial, 29 of 30 patients who could be evaluated were free of severe pain episodes for at least 12 consecutive months
• Developers: Vertex Pharmaceuticals and CRISPR Therapeutics

Other gene therapy milestones:

• LUXTURNA: AAV-based gene therapy for a rare inherited retinal dystrophy (RPE65 mutation) causing blindness; approved by FDA 2017
• Haemophilia B treatments: Gene therapies delivering functional copies of the clotting factor IX gene
• CAR-T cell therapy: Not CRISPR, but a form of gene therapy — immune cells are genetically engineered to target cancer cells; approved for certain leukaemias and lymphomas

7. The He Jiankui Affair — Germline Editing Controversy

The most consequential ethics controversy in modern biotechnology:

• November 2018: Chinese scientist He Jiankui announced — at the Second International Summit on Human Genome Editing in Hong Kong — that he had produced the world's first gene-edited babies
• What he did: He recruited couples where the father was HIV-positive; edited human embryos using CRISPR-Cas9 to disable the CCR5 gene (the protein HIV uses to enter cells), aiming to make the children resistant to HIV
• The babies: Twin girls born in October 2018 (pseudonyms Lulu and Nana); a third gene-edited baby was reportedly born later from the same experiment
• Global condemnation: The scientific community worldwide condemned the experiment as premature, dangerous, and ethically unjustifiable — HIV-positive parenthood can be managed without editing embryos; the CCR5 deletion may have other health consequences
• Legal outcome: On 30 December 2019, a Shenzhen court convicted He Jiankui of "illegal medical practice" and sentenced him to 3 years in prison and a fine of 3 million yuan (~US$430,000). He was released in April 2022.

Why this matters for UPSC: The case crystallised global concern about unilateral germline gene editing and triggered renewed calls for international governance frameworks.

8. Agricultural Applications of CRISPR

CRISPR is increasingly applied in agriculture, creating a distinct regulatory challenge (are CRISPR-edited crops "GMOs"?):

ICAR (Indian Council of Agricultural Research): India's primary agricultural research body is conducting CRISPR research on rice and wheat varieties for disease resistance and improved nutritional profiles.

9. Synthetic Biology

Synthetic biology goes beyond editing existing organisms — it involves designing and constructing new biological parts, devices, and systems, or redesigning existing natural biological systems.

Applications of synthetic biology:

• Biosensors: Bacteria engineered to detect pollutants, pathogens, or landmines in soil
• Living medicines: Engineered gut bacteria that detect and treat colorectal cancer
• Biofuels: Yeast and bacteria engineered to convert cellulose to ethanol more efficiently
• Biomanufacturing: Engineered microorganisms producing pharmaceuticals (insulin, artemisinin for malaria)
• Biological computers: DNA-based logic gates for ultra-dense data storage

10. Gene Drives — Ecological Risk and Promise

A gene drive is a CRISPR-based system designed to propagate a genetic change through an entire wild population much faster than normal Mendelian inheritance would allow (potentially spreading through a population in 10–20 generations).

Potential applications:

• Eliminating malaria by making mosquito populations (Anopheles gambiae) infertile or resistant to Plasmodium
• Controlling invasive species on islands

Risks:

• A gene drive released into a wild population cannot be recalled
• Ecological consequences of eliminating or radically altering a wild species are unpredictable
• Cross-border spread — a gene drive released in one country could spread globally
• Potential for misuse as a bioweapon

Gene drives are governed under the Cartagena Protocol on Biosafety (2000), a supplementary protocol to the Convention on Biological Diversity (CBD), though specific gene drive regulations are still evolving internationally.

11. India's Regulatory Framework

Regulatory challenge for CRISPR crops:

• Traditional GMOs involve inserting DNA from another species — clearly defined as "transgenic"
• CRISPR edits can be made without inserting foreign DNA, making the edited organism genetically indistinguishable from a naturally occurring mutant
• Many countries (USA, Japan, Argentina) exempt certain CRISPR edits from full GMO regulation; India's regulatory framework is still evolving on this question

Cartagena Protocol on Biosafety (2000): India is a signatory; governs the movement of Living Modified Organisms (LMOs) — primarily targeted at transgenic crops but increasingly discussed in the context of gene drives and synthetic biology.

12. Ethical Dimensions

Recent Developments (2024–2026)

BIRSA 101 — India's First Indigenous CRISPR Gene Therapy (November 2025)

India launched BIRSA 101 — the country's first indigenous CRISPR-based gene therapy for sickle cell disease — in November 2025, a collaboration between the Ministry of Tribal Affairs, AIIMS Delhi, and IGIB (Institute of Genomics and Integrative Biology, CSIR). The therapy uses enFnCas9, an enhanced version of the FnCas9 enzyme developed and patented by IGIB, providing high-precision editing with reduced off-target effects.

BIRSA 101 targets the HBB gene to correct the sickle cell mutation — a single nucleotide substitution (A to T at codon 6) — potentially offering a one-time cure. India has approximately 30 million sickle cell disease carriers and around 2 lakh patients, concentrated in tribal populations of Central and Western India. The scheme is funded under the National Sickle Cell Anaemia Elimination Mission (target: eliminate SCD by 2047, aligned with India@100).

UPSC angle: BIRSA 101, enFnCas9, sickle cell disease burden in India, tribal health dimension, and National Sickle Cell Anaemia Elimination Mission are Mains GS-3/GS-2 content.

BioE3 Policy and Gene Therapy Pipeline 2024

The BioE3 (Biotechnology for Economy, Environment, and Employment) Policy (August 2024) formally positions gene therapy as a priority vertical under "Precision Biotherapeutics." DBT-supported clinical trials include: (a) first-in-human Phase I gene therapy for Hemophilia A — results published in the New England Journal of Medicine; (b) gene editing therapy for Beta-Thalassaemia (IGIB); (c) mRNA-based protein replacement therapy for Hemophilia B.

India's regulatory framework for gene therapy is governed by the CDSCO's National Guidelines for Gene Therapy Product Development and Clinical Trials (2019), with the Drugs and Clinical Trials Rules 2019 providing the statutory framework. The RCGM (Review Committee on Genetic Manipulation) under DBT oversees all recombinant DNA/gene therapy research.

UPSC angle: BioE3 Policy gene therapy pipeline, Hemophilia A clinical trial (NEJM publication), RCGM oversight, and CDSCO gene therapy guidelines are Mains GS-3 content.

Global Gene Editing Ethics — WHO Framework and India 2024

The WHO's Expert Advisory Committee on Human Genome Editing published its final recommendations in 2021 and the governance framework was being implemented globally through 2024. The framework emphasises: no heritable human genome editing (germline editing) until safety/efficacy is established and broad social consensus exists; registries for somatic gene therapy clinical trials; and equitable access to gene therapy benefits.

India's RCGM prohibits germline editing research in humans, aligning with the global consensus. The 2018 He Jiankui case (China) — where twin girls with HIV-resistant CCR5 gene deletion were born from CRISPR-edited embryos — remains the defining case of unethical germline editing. India's regulatory gap: unlike the US (FDA oversight) or EU (EMA), India lacks a single dedicated agency for advanced therapy medicinal products (ATMPs) — a legislative gap BioE3 Policy seeks to address.

UPSC angle: WHO germline editing governance framework, He Jiankui case as ethical case study, India's RCGM, and the ATMP regulatory gap are GS-3/GS-4 ethics content.

Exam Strategy

For Prelims:

• Nobel Prize Chemistry 2020 = Jennifer Doudna + Emmanuelle Charpentier = CRISPR
• Casgevy = FDA approved December 2023 = first CRISPR therapy = sickle cell disease
• He Jiankui = 2018 = edited CCR5 gene = HIV resistance = 3 years prison = first gene-edited babies
• GEAC = under MoEFCC (not DBT — a common error)
• Cartagena Protocol = biosafety = under CBD

For Mains (GS3):

Questions typically ask: "Discuss applications and ethical concerns of CRISPR" or "What regulatory framework should govern gene editing in India?"

Useful structure:

1. What is CRISPR — brief mechanism (gRNA + Cas9)
2. Applications: somatic therapy (Casgevy), agriculture, synthetic biology
3. Controversies: He Jiankui, germline editing, gene drives
4. India's framework (GEAC, RCGM, DBT) and gaps
5. Way forward: international governance, equity in access, precautionary principle

Key distinction to always mention: Somatic (not heritable, ethically acceptable) vs germline (heritable, ethically controversial) gene editing.

Previous Year Questions (PYQs)

Prelims

• UPSC 2022: With reference to CRISPR-Cas9 technology, which of the following statements is/are correct?
• UPSC 2021: Consider the following: In which of these areas is CRISPR-Cas9 technology being used? (Agriculture, medicine, forensics)
• UPSC 2019: The Nobel Prize in Chemistry 2018 was for which breakthrough? (Directed evolution — different from 2020, important to not confuse)
• UPSC 2018: What is 'gene drive'? (Definition and potential applications)

Mains

• UPSC GS3 2023: "Gene editing technologies hold transformative promise but require robust governance frameworks." Discuss with reference to CRISPR and India's regulatory mechanisms.
• UPSC GS3 2021: What are the applications of gene-editing technology in medicine and agriculture? Examine the ethical and regulatory challenges in the Indian context.
• UPSC GS3 2019: Discuss the potential and limitations of CRISPR-Cas9 as a tool for treating genetic diseases. What ethical concerns does germline editing raise?
• UPSC GS3 2017: "Synthetic biology could be as disruptive as the digital revolution." Evaluate this claim in the context of India's biotechnology sector.